Browsing Tag
metabolic disease
7 posts
Are oral GLP-1 pills finally closing the credibility gap with injectables after ribupatide data
Are oral GLP-1 and GIP agonists becoming viable after ribupatide’s Phase 2 data? Explore what this shift means for obesity drug strategy.
Can OrsoBio’s TLC-6740 combination data reopen the race for post-GLP obesity differentiation?
OrsoBio’s TLC-6740 combo data hints at a new way to extend GLP-1 weight loss without higher doses. Read what this means for obesity drug development.
Innovent Biologics launches clinical trial for IBI3011 to target gout and inflammatory diseases in China
Find out how Innovent Biologics is targeting unmet needs in gout with IBI3011, a first-in-class anti-IL-1RAP antibody now in clinical trials. Read more.
Why Eli Lilly (NYSE: LLY) just joined the $1tn club—and what it means for obesity drug stocks
Find out how Eli Lilly’s weight-loss drug surge has pushed it past a $1 trillion valuation—and what that means for the industry!
Why investors are watching Ascletis Pharma’s monthly obesity shot as a potential GLP-1 disruptor
Ascletis Pharma reveals ASC36–ASC35 obesity combo with 51% greater weight loss vs tirzepatide. IND filing expected in 2026. Learn what’s next in its pipeline.
MetaVia unveils synergistic liver disease data on DA-1241 and Efruxifermin at ADA 2025
MetaVia unveils ADA 2025 pre-clinical data showing DA-1241 and Efruxifermin combo improves MASH liver inflammation and fibrosis beyond monotherapies.
Biomea Fusion posts 15% weight loss in primate model as BMF-650 nears IND for oral GLP-1 therapy
Biomea Fusion’s BMF-650 shows 15% weight loss in primates. Find out why investors are watching its IND filing and Phase I trial timeline for obesity treatment.